Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan.
Akira Fukutomi
No relevant relationships to disclose
Takuji Okusaka
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Kazuya Sugimori
No relevant relationships to disclose
Hideki Ueno
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Tatsuya Ioka
Research Funding - Taiho Pharmaceutical
Shinichi Ohkawa
No relevant relationships to disclose
Narikazu Boku
Consultant or Advisory Role - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Kenji Yamao
Consultant or Advisory Role - Taiho Pharmaceutical
Kazuhiro Mizumoto
Consultant or Advisory Role - Taiho Pharmaceutical
Junji Furuse
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Akihiro Funakoshi
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Takashi Hatori
No relevant relationships to disclose
Taketo Yamaguchi
No relevant relationships to disclose
Shinichi Egawa
No relevant relationships to disclose
Atsushi Sato
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yasuo Ohashi
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Ann-Lii Cheng
Consultant or Advisory Role - TTY Biopharm
Masao Tanaka
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical